Cidara Therapeutics, Inc. announced on March 18, 2025, that it would deliver two presentations at the 38th International Conference on Antiviral Research (ICAR), held from March 17-21, 2025, in Las Vegas, Nevada.
The presentations are set to highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388. Additionally, dose optimization models for evaluating CD388 in a Phase 3 study will be discussed.
The Phase 2b NAVIGATE trial completed enrollment of more than 5,000 participants in the United States and the UK. Prior Phase 1 and Phase 2a clinical data indicated that CD388, administered by subcutaneous injection, appeared well-tolerated and efficacious in healthy human volunteer studies, informing the planned Phase 3 development program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.